Serum free light chain quantitative assays: Dilemma of a biomarker.
Cigliana G et al. J Clin Lab Anal. 2017 Apr 26. doi: 10.1002/jcla.22243. [Epub ahead of print].

The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic.
Milani P et al. Am J Hematol. 2017 Apr 25. doi: 10.1002/ajh.24772. [Epub ahead of print].

Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response.
D’Auria F et al. Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14662. [Epub ahead of print].

Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation.
Andersen MN et al. Onco Targets Ther. 2017 Apr 4;10:1977-1982. doi: 10.2147/OTT.S124321. eCollection 2017.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
Rasche L et al. Blood. 2017 Apr 21. pii: blood-2017-03-774422. doi: 10.1182/blood-2017-03-774422. [Epub ahead of print].

A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?
Filonzi G et al. AJR Am J Roentgenol. 2017 Apr 18:1-7. doi: 10.2214/AJR.16.17219. [Epub ahead of print].

Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.
Sabatino R et al. Int J Mol Sci. 2017 Apr 12;18(4). pii: E804. doi: 10.3390/ijms18040804.

Musculoskeletal Imaging Findings of Hematologic Malignancies.
Navarro SM et al. Radiographics. 2017 Apr 7:160133. doi: 10.1148/rg.2017160133. [Epub ahead of print].

Monitoring of multiple myeloma by quantification of recurrent mutations in serum.
Rustad EH et al. Haematologica. 2017 Apr 6. pii: haematol.2016.160564. doi: 10.3324/haematol.2016.160564. [Epub ahead of print].

Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma.
Hu AX et al. Tumour Biol. 2017 Apr;39(4):1010428317694563. doi: 10.1177/1010428317694563.

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.
Qasaimeh MA et al. Sci Rep. 2017 Apr 4;7:45681. doi: 10.1038/srep45681.

Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.
Arteche-López A et al. Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.29. [Epub ahead of print].

A New Monoclonal Band in a Patient with Refractory Multiple Myeloma.
Willard N et al. Clin Chem. 2017 Apr;63(4):927-935. doi: 10.1373/clinchem.2016.270090.

Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB et al. PLoS One. 2017 Mar 28;12(3):e0174152. doi: 10.1371/journal.pone.0174152. eCollection 2017.